No, the Biotech Rally Isn’t Over

After big rallies by biotech stocks, the folks at Weeden wondered if the rally getting overdone. UBS analyst Matthew Roden and team think biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Puma Biotechnology (PBYI) and Achillion Pharmaceuticals (ACHN) can keep running. They explain why: Despite recent sector performance, we believe the drivers of biotech outperformance are [...]